Q2 2017 13F Holders as of 6/30/2017
-
Type / Class
-
Debt / NOTE 0.750% 8/1
-
Number of holders
-
25
-
Total principal
-
243M
-
Principal change
-
-1.5M
-
Total reported value, excl. options
-
$402M
-
Value change
-
+$4.75M
-
Number of buys
-
14
-
Number of sells
-
-9
-
Price
-
$1.66
Significant Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 as of Q2 2017
25 filings reported holding 53220KAD0 - LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 as of Q2 2017.
LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 has 25 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $243M of principal
.
Largest 10 bondholders include CITADEL ADVISORS LLC ($37M of principal), HIGHBRIDGE CAPITAL MANAGEMENT LLC ($27.5M of principal), CQS Cayman LP ($25M of principal), WELLS FARGO & COMPANY/MN ($20.7M of principal), SUSQUEHANNA INTERNATIONAL GROUP, LLP ($19.3M of principal), Calamos Advisors LLC ($12.5M of principal), BASSO CAPITAL MANAGEMENT, L.P. ($12.2M of principal), Mint Tower Capital Management B.V. ($12M of principal), CSS LLC/IL ($11.5M of principal), and ANGELO GORDON & CO., L.P. ($8.5M of principal).
This table shows the top 25 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.